Volixibat - Mirum Pharmaceuticals
Alternative Names: LUM-002; SAR-548304; SHP-626; Volixibat - Takeda; Volixibat potassiumLatest Information Update: 16 May 2025
At a glance
- Originator sanofi-aventis
- Developer Mirum Pharmaceuticals; Sanofi; Shire
- Class Anti-inflammatories; Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Primary biliary cirrhosis
- Phase II Intrahepatic cholestasis; Primary sclerosing cholangitis
- No development reported Cholestasis
- Discontinued Hypercholesterolaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 12 May 2025 Updated efficacy data from the phase IIb VANTAGE trial in Primary biliary cirrhosis released by Mirum Pharmaceuticals
- 29 Apr 2025 Updated efficacy and adverse events data from the phase IIb VANTAGE trial in Primary biliary cirrhosis released by Mirum Pharmaceuticals
- 15 Nov 2024 Efficacy and adverse event data from the clinical trial in Primary biliary cholangitis presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases 2024 (AASLD-2024)